Dr. Daniel Jeremy Kass, MD

Dr. Kass practices at Lifeline Physical Therapy - Warrendale in Warrendale, Pennsylvania.

Dr. Kass' NPI, 1629176995, was assigned on September 20, 2006. Dr. Kass graduated from New York University School of Medicine in 1999. Dr. Kass holds Pennsylvania license MD438861.

Dr. Kass' primary practice is Lifeline Physical Therapy - Warrendale, at 100 Fowler Road Suite 40, Warrendale, PA 15086. The practice phone is (724) 933-3280.

Dr. Kass' primary practice is Lifeline Physical Therapy - Warrendale in Warrendale, Pennsylvania. Dr. Kass is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Kass to 5 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kass practices, 9 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Kass' primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dmand AI has Dr. Kass' licenses on file in 2 states: Pennsylvania and New York.

CMS data shows 245 Medicare services from Dr. Kass across 4 procedure codes in 2024, for 137 Medicare patients. Medicare paid $14,717 for them.

CMS counts 137 Medicare patients who saw Dr. Kass in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kass' median patient age at 70, with 57% women.

In 2024, Dr. Kass wrote 649 Medicare Part D claims for 82 patients. 61% of them were for generic drugs. CMS names the drug for 563 of them, across 19 drugs with 11 or more claims each, at $1,041,226 in total drug cost. In 2023, CMS named 482 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Kass for performance year 2024, reported as part of a group. Dr. Kass accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kass as offering telehealth.

Dmand AI links 104 papers to Dr. Kass, published from 2011 to 2025. 2019 was the busiest year, with 7. The most frequent topics are Idiopathic Pulmonary Fibrosis, Lung and Fibroblasts. Dr. Kass has published most often in Am J Respir Crit Care Med. Dr. Kass' most frequent co-authors are Christopher James Ryerson, MD, Kerri Johannson, MD and Joseph M. Pilewski.

Dmand AI links Dr. Kass to 2 clinical trials. Conditions studied include Idiopathic Pulmonary Fibrosis, Death and Pulmonary Fibrosis.

CMS Open Payments shows 8 general payments to Dr. Kass from 3 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 90% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $2,806.

Dr. Kass graduated from New York University School of Medicine in 1999.